Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

OBJECTIVE: To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. STUDY DESIGN: Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. POPULATION: A total of 893 patients with...

Bibliografske podrobnosti
Main Authors:	Fisher, C, Dhainaut, J, Opal, S, Pribble, J, Balk, R, Slotman, G, Iberti, T, Rackow, E, Shapiro, M, Greenman, R
Format:	Journal article
Jezik:	English
Izdano:	1994

Podobne knjige/članki

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
od: Fisher, C, et al.
Izdano: (1993)

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
od: Peter Kirk, et al.
Izdano: (2021-05-01)

Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells
od: Huan Wang, et al.
Izdano: (2021-03-01)

Effectiveness and economic evaluation of rhTPO and rhIL-11 in the treatment of cancer therapy induced thrombocytopenia based on real-world research
od: Fa-Min Gong, et al.
Izdano: (2024-01-01)

Cardiorenal Syndromes and Sepsis
od: C. Chelazzi, et al.
Izdano: (2011-01-01)

Sepsis: syndrome or disease?
od: Ali Mohammad Sabzghabaee, et al.
Izdano: (2010-07-01)

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
od: Sarah Cooley, et al.
Izdano: (2019-07-01)

Pharmacokinetic Study of rhIL-18BP and Its Effect on Radiation-Induced Cytokine Changes in Mouse Serum and Intestine
od: Wanchang Cui, et al.
Izdano: (2022-12-01)

Production Design of Efficient Recombinant Human Interleukin-4 (rhIL-4) under Specific Promoter in Escherichia coli
od: Mahmoud Vahidi, et al.
Izdano: (2019-01-01)

Age, exercise, and the outcome of sepsis
od: Debasree Banerjee, et al.
Izdano: (2017-11-01)

Post-sepsis syndrome – an evolving entity that afflicts survivors of sepsis
od: Zachary Mostel, et al.
Izdano: (2019-12-01)

Quantitative phosphoproteomic analysis reveals chemoresistance-related proteins and signaling pathways induced by rhIL-6 in human osteosarcoma cells
od: Rui Zhang, et al.
Izdano: (2021-10-01)

Neurokinin-1 Receptor Antagonist Treatment in Polymicrobial Sepsis: Molecular Insights
od: Akhil Hegde, et al.
Izdano: (2010-01-01)

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors
od: Dan li, et al.
Izdano: (2024-07-01)

1044 High dose of rhIL-10 enhances CD8 T cell and NK cell mediated tumor cell killing in vitro
od: Elli Narvi, et al.
Izdano: (2023-11-01)

Macrophage Activation Syndrome in Viral Sepsis
od: Despoina Papageorgiou, et al.
Izdano: (2024-06-01)

Correction: rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors
Izdano: (2025-03-01)

Anti-myeloma efficacy of BCMA CAR-iNKT is enhanced with a long-acting IL-7, rhIL7hyFc
od: Julie O'Neal, et al.
Izdano: (2024-04-01)

621 A phase I study of autologous activated NK cells ± rhIL15 in children and young adults with refractory solid tumors
od: Nan Zhang, et al.
Izdano: (2023-11-01)

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
od: Miriam Y. Kim, et al.
Izdano: (2022-06-01)

IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice.
od: Abukar Ali, et al.
Izdano: (2015-01-01)

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma
od: Garcia Michael E, et al.
Izdano: (2007-12-01)

Dress syndrome with sepsis, acute respiratory distress syndrome and pneumomediastinum
od: Prabhas Prasun Giri, et al.
Izdano: (2011-01-01)

Sepsis-Induced Myocardial Depression and Takotsubo Syndrome
od: Mustafa Kemal Arslantaş, et al.
Izdano: (2015-08-01)

Abdominal Compartment Syndrome in Patients with Abdominal Sepsis
od: I. A. Kryvoruchko, et al.
Izdano: (2017-03-01)

Coasting Versus GnRH Antagonist Salvage for the Prevention of Ovarian Hyperstimulation Syndrome
od: Cavidan Gülerman, et al.
Izdano: (2013-12-01)

A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity
od: Punyadeera Chamindie, et al.
Izdano: (2010-01-01)

HIGH LEVEL OF IL -1 RECEPTOR ANTAGONIST AS A LETHALITY FACTOR IN PATIENTS WITH SURGICAL SEPSIS
od: V. V. Grebenyuk, et al.
Izdano: (2014-07-01)

Multiorgan dysfunction syndrome in sepsis: Is macrophage activation syndrome secondary to infection?
od: Arnab Nandy, et al.
Izdano: (2021-04-01)

A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.
od: Suputtamongkol, Y, et al.
Izdano: (2000)

Nosography of systemic inflammatory response syndrome, sepsis, severe sepsis, septic shock, and multiple organ dysfunction syndrome in internal medicine patients
od: Silvia Spoto, et al.
Izdano: (2015-09-01)

Spectral analysis of heart rate variability in the sepsis syndrome.
od: Garrard, C, et al.
Izdano: (1993)

Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome
od: Franck Trimoreau, et al.
Izdano: (2000-01-01)

Immunomodulation in sepsis-induced macrophage activation syndrome in children
od: Ashna Kumar, et al.
Izdano: (2023-01-01)

Research progress of sepsis complicated with capillary leakage syndrome
od: LIN Bai-bai, QIAN Feng-hua, QIAN Yi-ming, ZHAO Lei, SUN Qi, CHU Meng-yao, SHEN Meng-wen
Izdano: (2022-07-01)

Endocan, sepsis, pneumonia, and acute respiratory distress syndrome
od: Nathalie De Freitas Caires, et al.
Izdano: (2018-10-01)

Nonthyroidal illnesses syndrome in full-term newborns with sepsis
od: Maria Helena Baptista Nunes da Silva, et al.

Systemic inflammatory response syndrome in surgical patients with sepsis
od: Milić Dragan J., et al.
Izdano: (2004-01-01)

β1-blocker in sepsis
od: Daisuke Hasegawa, et al.
Izdano: (2021-05-01)

Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK
od: Marine Angé, et al.
Izdano: (2021-07-01)